Navigation Links
ADVENTRX CEO Selected by Combined Health Agencies as a 2012 Health Hero

SAN DIEGO, March 15, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that Brian M. Culley, its Chief Executive Officer, has been selected as a 2012 Health Hero by Combined Health Agencies of San Diego County. His nomination was submitted by the San Diego Chapter of the Sickle Cell Disease Association of America. The 18th Annual Health Hero Awards, organized by Combined Health Agencies, honors local companies and individuals for their contributions, dedication and commitment to the health of the San Diego community.

"Along with my ADVENTRX colleagues, I am honored to be recognized for our efforts to increase awareness of the fight against sickle cell disease," stated Brian M. Culley, Chief Executive Officer of ADVENTRX.  "There is a disappointing lack of advocacy on behalf of patients suffering with sickle cell disease, which may help explain the lack of safe and effective drugs for this lifelong disease that affects children typically within the first year of life.  We are proud to develop ANX-188 as a potential new treatment for sickle cell patients and to support the mission of increasing awareness and understanding of sickle cell disease."

About Combined Health Agencies

Established in 1970, Combined Health Agencies is a non-profit federation of local and national health agencies that serve the San Diego community. Collectively, the member agencies touch 1.6 million individuals, inspire 12,000 volunteers and invest in scientific and medical research projects.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on developing proprietary product candidates.  The Company's lead product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell disease.  We also are developing ANX-514, a novel, detergent-free formulation of the chemotherapy drug docetaxel.  More information can be found on the Company's web site at

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the Company's development plans for ANX-188, including the nature and timing of future clinical studies. Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and those indicated from the forward-looking statements are risks and uncertainties inherent in ADVENTRX's business, including, but are not limited to:  the potential for ADVENTRX to delay, reduce or discontinue current and/or planned development activities, partner its product candidates at inopportune times or pursue less expensive but higher-risk development paths if it is unable to raise sufficient additional capital as needed; ADVENTRX's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for delays in the commencement or completion of its planned clinical studies including as a result of difficulties or delays in completing manufacturing process development activities and manufacturing clinical trial material; the risk of suspension or termination of a clinical study including due to lack of adequate funding; the risk that planned clinical studies of our product candidates, including ANX-188, are not successful and, even if they are successful, that the FDA could determine they are not sufficient to support an NDAs for the product candidate; the risk that the FDA does not grant market approval of ADVENTRX's product candidates, including ANX-188, on a timely basis, or at all; ADVENTRX's reliance on third parties to assist in the conduct of important aspects of its product candidates' development programs, including the manufacture of clinical trial material, the conduct of clinical studies and regulatory submissions related to product approval, and that such third parties may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Meets with FDA to Discuss Development Plans for ANX-188
2. ADVENTRX Announces Closing of Public Offering
3. ADVENTRX Announces Public Offering of Stock
4. ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514
5. ADVENTRX Pharmaceuticals to Present at the 10th Annual BIOInvestor Forum Conference on October 26
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12
7. ADVENTRX Provides Update on All Three Pipeline Products
8. ADVENTRX Reports Second Quarter 2011 Financial Results
9. ADVENTRX Pharmaceuticals to Present at the 31st Annual Canaccord Genuity Growth Conference on August 11
10. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
11. ADVENTRX Reports First Quarter 2011 Financial Results
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of the ... 2016, at Caesars Palace in Las Vegas with a pre-conference session on a ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... Secura Consultants has prided itself for not only fulfilling the needs of advisers ... solutions at an affordable price and providing top-tier customer service. However, there's always ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and distributor ... Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , ... up-to-date with a version of Asterisk that will receive not only security fixes, ...
Breaking Medicine News(10 mins):